Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Our leadership team has made pivotal contributions to 13 FDA approvals (including recent MDD approval), $3.5B in M&A, and significant public company value creation.
As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and access.
Company Details
- Employees
- 25
- Founded
- -
- Address
- 220 5th Ave,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- New York, NY
Transcend Therapeutics Questions
Transcend Therapeutics's website is https://www.transcendtherapeutics.com/
Transcend Therapeutics's LinkedIn profile is https://www.linkedin.com/company/transcend-therapeutics
Transcend Therapeutics has
25 employees.
View email and phone details for 25
employees at Transcend Therapeutics.
Transcend Therapeutics's industry is
Biotechnology Research
Transcend Therapeutics's top competitors are
Gilgamesh Pharmaceuticals,
Biospherix, Llc,
Aethon Therapeutics,
Protara Therapeutics,
Oncusp Therapeutics,
Nuvation Bio,
Lexeo Therapeutics,
Delcath Systems,
Immunic Therapeutics,
Dianthus Therapeutics, Inc..
Transcend Therapeutics's categories are Biotechnology Research
Transcend Therapeutics's founding year is 2021
